With Blenrep's revival, GSK dials up long-term sales goal—again—despite RSV vaccine woes
After re-adding Blenrep to its portfolio, GSK now expects sales to reach more than £40 billion in 2031. The company's previous target was £38 billion.
After re-adding Blenrep to its portfolio, GSK now expects sales to reach more than £40 billion in 2031. The company's previous target was £38 billion.
